Kinetics of thermal degradation of polymeric materials is usually studied by weight loss at a constant temperature or during heating. Hence, the activation energy and other kinetic parameters of the thermal destruction process are determined. One of the fastest and most accessible methods for studying the kinetics of these processes is TGA. Weight methods of TGA do not provide an opportunity to judge the proportion of gaseous degradation products. This is especially true for processes associated with the release of hydrogen and other substances with low molecular weights, the accuracy of determining the amount of which by the weight method is low. Meanwhile, the study of the gas evolution process can provide additional information about the kinetics and mechanism of thermal destruction processes. Of great interest is also the joint study of the total weight loss and gas evolution during the polymer heating. Using mass spectrometry, IR spectroscopy combined with thermal analysis (TGA/DSC-IR and TGA/DSC-MS) we have defined product composition and thermal destruction kinetics. As a result of the TGA/DSC-MS study of gaseous products of thermolysis in nitrogen atmosphere, there were found products with 44, 45, 59, 60, 68, and 88 phr. Quite a similar pattern for p-PGFPh:AA copolymers is also observed in TGA/DSC-IR studies: the same products and the same temperature range. However, in contrast to the TGA/DSC-MS study, CO release was also recorded by this method (weak signal). Kinetic characteristics of the processes were determined based on Friedman, Ozawa-Flynn-Wall and modified NPC methods. Obtained values of the activation energy and thermodynamic characteristics make it possible to predict the composition of polymers, which make a significant contribution to the development of theoretical ideas about the features of the physicochemical properties of polymers.

Influenza is a disease of significant morbidity and mortality. The number of anti-influenza drugs is small; many of them stimulate the appearance of resistant strains. This article presents the results of assessing the antiviral activity of 1,2,3-triazole-containing derivatives of alkaloid lupinine for their ability to suppress the reproduction of orthomyxoviruses (influenza viruses: A/Vladivostok/2/09 (H1N1) and A/Almaty/8/98 (H3N2)). The ability of (1S,9aR)-1-[(1,2,3-triazol-1-yl)-methyl]octahydro-1H-quinolizines with aryl-, 4-((4-formylphenoxy)methyl)- or 4-((3-tert-butyl-5-ethyl-2-hydroxy-benzoyloxy)methyl)- substituents at the C-4 position of the triazole ring to reduce the infectivity of the virus when processing virus-containing material was established, indicating good prospects for the studied compounds as virucidal agents affecting extracellular virions. The experimental results demonstrated that the triazolyl lupinine derivatives exhibited varying degrees of affinity for both hemagglutinin and neuraminidase proteins. Furthermore, these compounds demonstrated inhibitory effects on the replication of influenza viruses with different antigenic subtypes. The obtained biological data are in agreement with the results of molecular docking, which showed strong binding energies of the investigated compounds under study with biological targets—hemagglutinin and neuraminidase proteins. Following the evaluation of antiviral efficacy among the studied triazolyl derivatives of lupinine, four compounds have been identified for subsequent comprehensive in vitro and in vivo investigations to further elucidate their antiviral properties.

Achillea nobilis and its subspecies (A. nobilis subsp. neilreichii and A. nobilis subsp. sipylea) have been traditionally used in various ethnomedical systems across Eurasia. However, comprehensive studies on their phytochemical composition and pharmacological properties are still insufficient. This review aims to provide a critical synthesis of current knowledge regarding the botanical characteristics, geographic distribution, traditional applications, chemical constituents, and pharmacological effects of A. nobilis A structured search was conducted using eight scientific platforms, including Scopus, PubMed, Web of Science, Google Scholar, Science.gov, ScienceDirect, JSTOR, and BASE. Keywords related to phytochemistry, pharmacology, and ethnomedicine were applied, and a total of 28,000 records were initially retrieved. After a multi-stage screening process based on inclusion and exclusion criteria, 167 peer-reviewed publications from 1952 to 2023 were selected for detailed evaluation. Findings reveal a diverse range of bioactive compounds, such as flavonoids, monoterpenes, sesquiterpenes, and sesquiterpene lactones, which demonstrate antioxidant, antimicrobial, anti-inflammatory, antinociceptive, antispasmodic, and anticonvulsant activities. Most studies have focused on aerial parts and water-based extracts, while the root chemistry and organ-specific metabolite profiles remain largely unexplored. This review highlights the therapeutic potential of A. nobilis and underscores the need for future studies using multi-omics and advanced analytical techniques to support its development in pharmaceutical and nutraceutical applications.

This review systematically compiles and evaluates current research on the ethnopharmacology, phytochemistry, pharmacological effects, and the clinical potential of plants of the genus Ribes L. Ribes species have long been used in traditional medicine for cardiovascular diseases, hepatitis, gastrointestinal ailments, hyperlipidemia, and detoxification, owing to their rich content of phenolic glycosides, flavonoids, proanthocyanidins, and polysaccharides. We analyze data from in vitro, in vivo, and clinical studies, focusing on antioxidant, anti-inflammatory, antibacterial, antiviral, antitumor, and vision-protective properties of extracts and isolated compounds. Particular attention is given to R. nigrum, a species recognized in French and British pharmacopeias for its antioxidant, anti-inflammatory, antimicrobial, and immunomodulatory properties. Our synthesis reveals significant gaps: many Ribes spp. remain poorly characterized chemically; toxicology and pharmacokinetics are seldom studied; clinical trials are limited in number and rigor. We propose that future research should prioritize the comprehensive metabolomic and chemoprofiling of understudied Ribes species; standardized safety and dosage studies; the elucidation of absorption, distribution, metabolism, and excretion (ADME) of key bioactives; and well-designed randomized clinical trials to validate traditional uses and establish therapeutic efficacy. Our review demonstrates that Ribes spp. are promising sources for novel phytopharmaceutical agents and functional foods, but that translational and regulatory research is essential to move from traditional claims toward evidence-based medical applications.

Introduction. Evaluation of the content of impurities is the most important step in confirming the safety and efficacy in the quality control of the medicinal product. Aluminum, being an acceptable impurity in a number of pharmaceutical substances, can adversely affect the human body, as a result of which its content is normalized. The admixture of aluminum in the State Pharmacopoeia of the Russian Federation XV is determined by the spectrofluorimetric method using the ligand – 8-hydroxyquinoline in chloroform. In the present work, it is proposed to replace 8-hydroxyquinoline with the more accessible rutin, which also forms fluorescent complexes with metals. This approach involves the exclusion of the stage of extraction of the aluminum complex into chloroform from sample preparation, which improves the accuracy of the technique, and the replacement of chloroform has a positive effect on safety.Aim. To create an alternative approach for the spectrofluorimetric determination of aluminum impurities using rutin and "potassium chloride" as an active pharmaceutical ingredient.Materials and methods. The following substances and reagents were used as research materials: CRS of aluminum ion 1 mg/ml (LLC "EKROSHIM", Russia), CRS of iron ion (II) 1 mg/ml (LLC "EKROSHIM", Russia), CRS of zinc ion 1 mg/ml (LLC "EKROSHIM", Russia), CRS of lead-ion 1 mg/ml (LLC "EKROSHIM", Russia), CRS nickel-ion 1 mg/ml (LLC "EKROSHIM", Russia), CRS copper-ion 1 mg/ml (LLC "EKROSHIM", Russia), chromium (III) cation standard 1 mg/ml (imp., Sigma-Aldrich, USA) rutin (imp., Sichuan Guangsong Pharmaceutical Co., Ltd., China), ammonium acetic acid (imp., Molekula GmbH, Germany), glacial acetic acid (chemically pure, JSC "Base No. 1 Himreaktivov", Russia), potassium chloride (pharmaceutical substance, LLC "MZHR", Russia). The spectrofluorimetric study was carried out on an FL 6500 instrument (PerkinElmer Inc., USA). The aluminum impurity content was also evaluated using an Optima 8000 inductively coupled plasma atomic emission spectrometer (ICP AES) (PerkinElmer Inc., USA) and a Multi-Element Solution standard sample (PerkinElmer Inc., USA).Results and discussion. The approach given in the article eliminates the use of 8-hydroxyquinoline in chloroform and replaces it with rutin in 70 % ethyl alcohol. The aluminum-rutin complex has an excitation wavelength at 445 nm and an emission wavelength at 565 nm. The proposed method was tested on the substance "Potassium chloride" to assess the indicator "Aluminum", the content of which should not exceed 0.0001 %. Method validation was carried out according to three parameters "Specificity", "Linearity" and "Limit of detection". Comparison of the data obtained was carried out using atomic emission spectroscopy, during which the relevance of the technique was proved.Conclusion. An ergonomic approach has been developed for the spectrofluorimetric determination of aluminum impurities using rutin with approbation on the substance "Potassium chloride". The results obtained during the experiment were confirmed by the ICP AES method.

Oxytropis glabra DC, a Fabaceae species distributed across Central Asia, is characterized by a dual biological profile encompassing pronounced toxicity alongside promising pharmacological potential. This review synthesizes current knowledge on its phytochemistry, bioactivity, and toxicological liabilities to clarify the plant’s risk–benefit landscape. The objectives are to summarize the dominant classes of metabolites identified in O. glabra, evaluate their toxicological and therapeutic relevance, and identify key gaps limiting translational research. O. glabra contains a diverse array of secondary metabolites, with quinolizidine and indolizidine alkaloids, including swainsonine, anagyrine, thermopsine, and sparteine, representing the primary determinants of toxicity. These compounds are associated with teratogenicity, neurotoxicity, and locoism through mechanisms involving α-mannosidase inhibition, disruption of glycoprotein processing, and impaired lysosomal homeostasis. In contrast, flavonoids such as quercetin, isoquercitrin, and kaempferol derivatives exhibit antioxidant, anti-inflammatory, hepatoprotective, and cardioprotective effects, while triterpenoid saponins and fatty acids contribute additional cytoprotective and metabolic activities. Despite extensive reports on both toxic and bioactive constituents, critical gaps remain regarding chemotype variability, dose–response relationships, and pharmacokinetics, which currently constrain therapeutic exploitation. Future research should prioritize defining safe exposure thresholds, elucidating structure–activity relationships, and developing standardized extracts or optimized derivatives that balance efficacy and safety. This integrative perspective highlights O. glabra as a chemically rich but biologically ambivalent species whose toxicological risks and pharmacological opportunities warrant systematic mechanistic investigation.